IDEXX Laboratories (IDXX) to Release Quarterly Earnings on Monday

IDEXX Laboratories (NASDAQ:IDXX) is expected to release its Q4 2025 results before the market opens on Monday, February 2nd. Analysts expect IDEXX Laboratories to post earnings of $2.93 per share and revenue of $1.0723 billion for the quarter. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.80 EPS. On average, analysts expect IDEXX Laboratories to post $12 EPS for the current fiscal year and $14 EPS for the next fiscal year.

IDEXX Laboratories Stock Up 0.4%

Shares of NASDAQ:IDXX opened at $693.85 on Monday. The firm has a market capitalization of $55.40 billion, a PE ratio of 55.02, a price-to-earnings-growth ratio of 3.71 and a beta of 1.67. IDEXX Laboratories has a 1 year low of $356.14 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The firm’s 50-day moving average is $705.83 and its two-hundred day moving average is $656.34.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by company insiders.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtus Advisers LLC purchased a new stake in IDEXX Laboratories during the third quarter worth approximately $26,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth approximately $36,000. Johnson Financial Group Inc. boosted its holdings in shares of IDEXX Laboratories by 1,475.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 63 shares of the company’s stock valued at $40,000 after buying an additional 59 shares in the last quarter. Finally, Pin Oak Investment Advisors Inc. purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $60,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. Morgan Stanley upped their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. BTIG Research upped their price objective on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. UBS Group increased their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research note on Monday, November 3rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $763.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.